Stockreport

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018 [Reuters]

Calithera Biosciences, Inc.  (CALA) 
Last calithera biosciences, inc. earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: calithera.com
PDF BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018 | Reuters Reuters Staff 1 [Read more]